Tazemetostat in Relapsed/Refractory Follicular Lymphoma: A Propensity Score–Matched Analysis of E7438-G000-101 Trial Outcomes

Opening their discussion on relapsed/refractory follicular lymphoma (R/R FL), expert participants review the spectrum of available treatments in this setting.

Drs Cheson and Park briefly review previous data from the E7438-G000-101 trial on tazemetostat in patients with wild-type or EZH2-mutant R/R FL, and then describe the findings of a more recent 2022 propensity score-matched analysis of the data that was intended to address baseline clinical differences between the two patient populations.

Closing out their review of tazemetostat in R/R FL, participants consider its practical use in practice alongside other novel treatment modalities.

Expert hematologist-oncologists discuess the E7438-G000-101 clinical trial and consider the EZH2 inhibitor tazemetostat as a treatment for relapsed/refractory follicular lymphoma.